Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FRRJ8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,844
Award facts
- Contract value 100% obligated
- $11,844.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,844.15 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 MG/ML syringes. This firm fixed-price delivery order, issued on December 29, 2025, with an ultimate completion date of January 21, 2026, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA—specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative—a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V master contract, awarded November 13, 2025, carries a ceiling value of $499,999,999 with a completion date of December 31, 2036, and includes a 30-month base period followed by three 30-month option periods. The contractor's established performance across a diverse pharmaceutical portfolio—including specialty biologics, oncology treatments, vaccines, and emergency medications—demonstrates its capability to fulfill the specialized requirements of military healthcare operations globally. This delivery order represents one of numerous purchases the company has fulfilled for the DLA Medical Supply Chain division, positioning DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical distribution network.
Quick answers
Who was awarded contract SPE2DR26FRRJ8?
SPE2DR26FRRJ8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FRRJ8 worth?
The government has obligated $11,844 on SPE2DR26FRRJ8.
Is contract SPE2DR26FRRJ8 an order under another contract?
Yes. SPE2DR26FRRJ8 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRJ8 competed?
The extent of competition for SPE2DR26FRRJ8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award